Loading organizations...
Key people at Brainsway.
BrainsWay is a medical technology company based in Jerusalem, Israel, and Burlington, Massachusetts, that develops noninvasive neurostimulation treatments for mental health disorders using its proprietary Deep Transcranial Magnetic Stimulation platform. The enterprise provides medical devices designed to stimulate deep brain areas to treat major depressive disorder, obsessive-compulsive disorder, and smoking addiction. Operating as a publicly traded entity dual-listed on the NASDAQ and the Tel Aviv Stock Exchange, the firm utilizes technology originally patented by the NIH and holds multiple clearances from the FDA. The company supplies its equipment to a global network of over 800 healthcare providers through an all-you-can-treat pricing model. Since the beginning of 2024, the business has closed at least ten enterprise deals totaling more than $1.3 million in new revenue. The international medical device manufacturer was officially established in the year 2003.
Key people at Brainsway.
BrainsWay is a global leader in noninvasive neurostimulation treatments for mental health disorders, specializing in its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform. Founded in 2003 and dual-listed on NASDAQ and the Tel Aviv Stock Exchange (TASE), the company develops advanced devices targeting conditions like major depressive disorder (including anxious depression), obsessive-compulsive disorder (OCD), and smoking addiction, with ongoing trials for additional psychiatric, neurological, and addiction disorders.[1][2] It serves psychiatrists, doctors, hospitals, and medical centers, addressing unmet needs in patients unresponsive to traditional treatments by offering clinically proven, stigma-reducing options that improve access to mental healthcare.[1][2]
The company's growth momentum stems from its Burlington, MA, and Jerusalem offices, a robust body of clinical evidence, and a mission to make mental health reachable for all through bold neuroscience advancements.[1]
BrainsWay was founded in 2003 in Jerusalem, Israel, emerging from a vision to pioneer noninvasive brain stimulation technologies amid rising needs for effective mental health treatments.[1][2] Headquartered in Jerusalem with U.S. operations in Burlington, MA, the company has evolved from initial Deep TMS development to a commercial-stage leader with FDA clearances and global reach, dual-listed on NASDAQ and TASE.[1][2] Key pivotal moments include building an unparalleled clinical evidence base and expanding indications, driven by a commitment to unconventional thinking and patient impact—everyone knows someone affected by mental illness, yet awareness of options like Deep TMS remains low, fueling early traction through awareness efforts.[1]
BrainsWay rides the wave of neuroscience and digital therapeutics, capitalizing on growing mental health demands post-pandemic, where traditional medications and therapy fall short for millions.[1] Timing is ideal amid market forces like rising awareness of noninvasive brain stimulation, regulatory nods (e.g., FDA for key indications), and tech-health convergence enabling precise, stigma-free interventions.[1] It influences the ecosystem by advancing clinical standards, promoting Deep TMS as a mainstream option, and fostering inclusive mental healthcare access, potentially reshaping treatment paradigms for disorders affecting vast populations.[1]
BrainsWay is poised for expansion through new trial readouts in neurological and addiction spaces, leveraging its evidence moat to capture share in the booming neurostimulation market.[1] Trends like AI-enhanced personalization and global mental health investment will propel it, evolving its influence from niche innovator to ecosystem shaper in accessible neuroscience. As a dual-listed pioneer transforming lives where others can't, BrainsWay exemplifies how bold tech redefines mental health reach.[1]
